Gamma counting protocols for the accurate quantification of $^{225}$Ac and $^{213}$Bi without the need for a secular equilibrium between parent and gamma-emitting daughter

Dayana Castillo Seoane1,2*, Marijke De Saint-Hubert2, Stephen Ahenkorah3,4, Clarita Saldarriaga Vargas2,5, Maarten Ooms3, Lara Struelens2 and Michel Koole1

Abstract

Background: Quantification of actinium-225 through gamma counter measurements, when there is no secular equilibrium between actinium-225 and its gamma emitting daughters bismuth-213 and/or francium-221, can provide valuable information regarding the possible relocation of recoiled daughters such that related radiotoxicity effects can be evaluated. This study proposes a multiple time-point protocol using the bismuth-213 photopeak with measurements before secular equilibrium between actinium-225 and bismuth-213, and a single time-point protocol using both the francium-221 and bismuth-213 photopeak while assuming secular equilibrium between actinium-225 and francium-221 but not between bismuth-213 and actinium-225.

Results: Good agreement (i.e. 3% accuracy) was obtained when relying on a multiple time-points measurement of bismuth-213 to quantify both actinium-225 and excess of bismuth-213. Following scatter correction, actinium-225 can be accurately quantified using the francium-221 in a single time-point measurement within 3% of accuracy. The analysis performed on the stability data of $[^{225}\text{Ac}]\text{Ac-DEPA}$ and $[^{225}\text{Ac}]\text{Ac-DOTA}$ complexes, before secular equilibrium between bismuth-213 and actinium-225 was formed, revealed considerable amounts of unbound bismuth-213 (i.e. more than 90%) after 24 h of the radiolabeling most likely due to the recoiled daughter effect.

Conclusion: Both protocols were able to accurately estimate $^{225}$Ac-activities provided the francium-221 energy window was corrected for the down scatter of the higher-energy gamma-emissions by bismuth-213. This could prove beneficial to study the recoiled daughter effect and redistribution of free bismuth-213 by monitoring the accumulation or clearance of bismuth-213 in different tissues during biodistribution studies or in patient samples during clinical studies. On the other hand, the single gamma counter measurement protocol, although required a 30 min waiting time, is more time and cost efficient and therefore more appropriate for standardized quality control procedures of $^{225}$Ac-labeled radiopharmaceuticals.

Keywords: Actinium-225, Bismuth-213, Francium-221, Gamma counter, Radiopharmaceutical quality control, Recoiled daughter effect

*Correspondence: marijke.de.saint-hubert@sckcen.be

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Introduction

Targeted alpha-therapy (TAT) has shown promising results when overcoming resistance to β-emitters in clinical applications (Kratochwil et al. 2014; Ballal et al. 2020). The efficiency of α-particles relies on their short penetration range within tissue (40–100 μm, Allen et al. 2014) and their high linear energy transfer (LET). $^{225}$Ac (actinium-225) is considered a promising candidate for TAT and a highly cytotoxic radionuclide due to its relatively long half-life (9.9 days) and the yield of a total of four α particles $^{221}$Fr (francium-221): 4.9 min half-life, 6 MeV α-particle; $^{217}$At (astatine-217): 32.3 ms half-life, 7 MeV α-particle; $^{213}$Bi (bismuth-213): 45.6 min half-life, 6 MeV α-particle; $^{213}$Po (polonium-213): 4.2 μs half-life, 8 MeV α-particle) in its decay chain. In addition, two gamma rays are emitted in the decay chain, 218 keV [11.4%] by $^{221}$Fr and 440 keV [25.9%] by $^{213}$Bi, which can be used for activity measurements. Indeed, most preclinical studies report $^{225}$Ac activities which are based on activity measurements of $^{213}$Bi or $^{221}$Fr while assuming secular equilibrium (SEq) between $^{225}$Ac and the measured daughter (Kruijff et al. 2019; Miederer et al. 2004a; Borchardt et al. 2003; Beyer et al. 1990), which means activity measurements based on the gamma emissions by either $^{221}$Fr or $^{213}$Bi are approximately equal to the activity of $^{225}$Ac. However, emission of a high-energy α particle can cause nuclear recoil effect (Kozempel et al. 2018). This recoil energy experienced by the daughter nuclei is sufficient to break the chemical bond between the daughter and the targeting vector (Kruijff et al. 2015), resulting in the so-called recoiled daughter effect (RDE) and causing at least partial release of radioactive daughter nuclei from the original targeting molecule or delivery vehicle (Kruijff et al. 2015). Loss of affinity to the molecular carrier can lead to a redistribution of recoiling radioactive daughters and induce radiation related side effects, such that RDE is often assumed to be the main cause of radiotoxicity for the organs at risk (OAR) and one of the main reasons for limiting the amount of activity of $^{225}$Ac-labeled radionuclides administered to patients (Ballal et al. 2020; Kratochwil et al. 2017, 2015; Khreish et al. 2020; Cordier et al. 2010). Redistribution of recoiled daughter radionuclides can also offset the SEq between $^{225}$Ac and daughter radionuclides, such that indirect measurement of the activity concentration of $^{225}$Ac by measuring the activity concentration of its gamma-ray emitting daughters $^{221}$Fr or $^{213}$Bi can be biased. Only a few studies (Kruijff et al. 2019; Miederer et al. 2004a, 2008; Poty et al. 2019; Nedrow et al. 2017; Schwartz et al. 2011; Song et al. 2009) have considered measurements before and during SEq between $^{225}$Ac and $^{213}$Bi, to evaluate the relocation of $^{213}$Bi, and in very limited cases also between $^{225}$Ac and $^{221}$Fr, to evaluate the relocation of $^{221}$Fr. Recoiling $^{213}$Bi was reported to have affinity to kidney tissue (Kruijff et al. 2019; Song et al. 2009; Drecoll et al. 2009), while $^{221}$Fr was associated with uptake in the gastrointestinal tract (Miederer et al. 2004b) and kidneys (Song et al. 2009). However, it should be noted that relocation of $^{221}$Fr is generally not considered as relevant because of the very short physical half-life of $^{221}$Fr (4.9 min), such that $^{221}$Fr is considered as the closest proxy to quantify $^{225}$Ac activity concentrations.

In the context of TAT, gamma counting (GC) is a frequently used technique for ex vivo quantification of $^{225}$Ac-labeled radiopharmaceuticals (Castillo Seoane et al. 2020), especially since in vivo nuclear imaging techniques, such as single-photon emission computed tomography (SPECT), have limited potential to allow accurate quantitative imaging of $^{225}$Ac concentrations in tissues because of the low branching ratio
of gamma-emissions in the decay chain and the low administered activities. Therefore, other measurement techniques, such as GC, represent an asset for dosimetry and radiotoxicity estimates, both preclinically and clinically. In a preclinical setting, GC allows biodistribution studies of $^{225}$Ac-labeled radiopharmaceuticals to estimate the absorbed doses by tumoral and healthy tissue. In addition, GC provides valuable information regarding the possible relocation of recoiled daughters, which is of interest to evaluate related radiotoxicity effects. In a clinical setting, GC measurements of blood and urine samples can be considered to determine plasma and renal clearance of radiopharmaceuticals, which in turn can be used for compartmental modeling of pharmacokinetics to estimate the radiation burden to OAR (Siegel et al. 1999).

In addition, GC measurements play an important role in the quality control (QC) of $^{225}$Ac-labeled radiopharmaceuticals to confirm sufficiently high radiochemical yield (RCY) before administration to patients. For this purpose, the activity distribution on an instant thin-layer liquid chromatography (iTLC) strip is analyzed using GC measurements to estimate the fraction of bound and unbound $^{225}$Ac and its daughter $^{213}$Bi. These GC measurements are usually based on the gamma emissions by $^{221}$Fr, which is at SEq with $^{225}$Ac within approximately six half-lives of $^{221}$Fr (~ 30 min) (Hooijman et al. 2021).

However, limited research has been done on GC measurements to quantify $^{225}$Ac activity when there is no SEq between $^{225}$Ac and its gamma emitting daughters $^{213}$Bi and/or $^{221}$Fr. Generally, GC measurements are delayed ensuring sufficient time for $^{213}$Bi to reach SEq with $^{225}$Ac, and to provide an unbiased estimation of the $^{225}$Ac-activity. The limitation of this approach is that, once in SEq, any additional $^{213}$Bi activity which was originally present in the measured sample before the start of the GC measurements cannot be traced back. Nonetheless, there is a growing interest to quantify $^{213}$Bi activity which is not related to the parent–daughter decay of $^{225}$Ac, but that is generated by the potential RDE and relocation of $^{213}$Bi. Therefore, the aim of this study is to develop and validate GC protocols to accurately quantify both $^{225}$Ac activity and a potential accumulation or clearance of $^{213}$Bi activity compared to SEq between $^{225}$Ac and $^{213}$Bi. We proposed (1) a multiple time-point protocol using the $^{213}$Bi photopeak with measurements before SEq between $^{225}$Ac and $^{213}$Bi, and (2) a single time-point protocol using both the $^{221}$Fr and $^{213}$Bi photopeaks, while assuming SEq between $^{225}$Ac and $^{221}$Fr but not between $^{213}$Bi and $^{225}$Ac. Using these two protocols, we evaluated the amount of unbound $^{213}$Bi for two different chelators $[^{225}$Ac]$\text{Ac-DEPA}(7-[2-(bis-carboxymethylamino)-ethyl]-4,10-bis-carboxymethyl-1,4,7,10-tetraazacyclododec-1-yl-acetic acid) and $[^{225}$Ac]$\text{Ac-DOTA} (1,4,7,10-Tetraazacyclododecane-1, 4,7,10-tetracetic acid) using iTLC strips after incubation in human serum to evaluate stability and RDE as part of QC tests after radiolabeling.

**Materials and methods**

**Radioisotopes and preparation of $[^{225}$Ac]$\text{-labeled constructs**

$^{225}$Ac samples were obtained from recurrent (trimestral, 6 MBq) milkings of an in-house $^{229}$Th stock obtained from a processed $^{229}$Th capsule as described by Boden et al. (2017). Milkings were performed with the aid of a tandem system of extraction chromatography columns using TEVA and DGA columns obtained from TrisKem, France. A first batch of $^{225}$Ac was used to evaluate the GC linearity and the effect of the sample volume variation...
on the GC detection efficiency (for details on the sample volume variations see Additional file 1).

Additionally, ±1.3 MBq of $^{225}$Ac was used to elute 1.19 MBq of $^{213}$Bi (using 0.1 M HCl/0.1 M NaI) from an $^{225}$Ac/$^{213}$Bi generator loaded with an AG MP-50 cation exchange resin (Ahenkorah et al. 2021). The eluate $^{213}$Bi$_4^{213}$Bi$_5^{2-}$ was used to prepare two samples, one containing $^{225}$Ac in SEq with $^{213}$Bi and $^{221}$Fr for the GC calibration, and one containing pure $^{213}$Bi to determine the photon scatter contribution of $^{213}$Bi gamma-emissions in the photopeak window of $^{221}$Fr.

Two other solutions of $^{225}$Ac doped with additional $^{213}$Bi were prepared to create a mixture of $^{225}$Ac in SEq with $^{213}$Bi and additional, pure $^{213}$Bi, to simulate non-equilibrium conditions between $^{225}$Ac and $^{213}$Bi. As such, the total activity of $^{213}$Bi was given by:

$$A_{\text{total}} = A_{^{213}\text{Bi}} + A_{^{225}\text{Ac}}$$

where $A_{^{225}\text{Ac}}$ is the activity of $^{213}$Bi in SEq with $^{225}$Ac. This was done by starting from a solution (~0.5 mL) of $^{225}$Ac in SEq with its decay progeny and adding 0.2 mL (and 0.3 mL) of the stock solution of pure $^{213}$Bi to 0.3 mL (and 0.2 mL) of the solution of $^{225}$Ac to obtain two samples with additional $^{213}$Bi activity (total sample volume ~0.5 mL).

$^{225}$Ac-constructs were synthesized by adding $[^{225}\text{Ac}]\text{Ac(NO}_3\text{)}_3$ (1–2 MBq, 100 µL, 0.05 M) to a Tris–HCl buffer (0.37 M, pH 8.5, chelex treated) solution containing DEPA or DOTA (50 µM) and reacting in a glass vial for 60 min at 95 °C. $^{225}$Ac-constructs were purified using a C$_{18}$ Plus Sep-Pak cartridge (Waters Co., Milford, MA, USA) by loading the reaction mixture, rinsing with water (5 mL) to remove unreacted $[^{225}\text{Ac}\text{Ac(NO}_3\text{)}_3$, and eluting the purified complex with absolute ethanol (0.5 mL) as described by Cassells et al. (2021). After purification, radiolabeled aliquots were applied immediately to the test media.

The radioactive composition of all reference samples (i.e. stock solutions) were determined via high-resolution gamma spectrometry analysis using a high-purity germanium (HPGe) detector (Mirion-Canberra, Meriden, USA) calibrated for photon energy and detection efficiency. $^{225}$Ac quantities were determined indirectly via measurements of $^{221}$Fr and $^{213}$Bi photopeaks once SEq was established. $^{213}$Bi quantities were determined via measurement of a pure $^{213}$Bi sample as fast as possible after elution. The content mass of the sample was verified gravimetrically and the exact volumes of the radioactive samples in each test tube were determined by weighing each tube before and after filling with an analytical balance (model ABP-200-4M; KERN & SOHN GmbH, Germany). The reference activity in each test tube was determined from the volume of each sample and the activity concentration of the reference stock solution. The relative statistical uncertainty of the reference activity concentration of each of the calibration stock solutions was always within 3.2% at 95% CI (coverage factor $k = 2$).

**Gamma counter measurements**

Gamma counter activity measurements were done in a 2480 Wizard$^2$ gamma counter (Perkin Elmer, Waltham, MA, USA) using a measurement protocol optimized to limit the overall measurement uncertainty (cfr. details in the Additional file 1). This gamma counter consists of a single 75-mm-diameter and 80-mm-high NaI(Tl) well-type detector. Each radioactive sample was measured for 60 s in a standard tube (5 mL plastic vials of 75 mm
height and 12 mm diameter), using a fixed energy window of 175–282 keV (EW 221Fr) and 378–520 keV (EW 213Bi) corresponding to the main photopeaks of 221Fr (218 keV) and 213Bi (440 keV), respectively. The measurement in each EW setting was automatically corrected for dead time, background, and measurement time and expressed as counts per minute (CPM).

First, the linear range of GC measurements for the two energy windows was determined, together with the GC calibration factor (CF). For the impact of different sample volumes on the detection efficiency, we refer to the Additional file 1.

Assuming SEq between 225Ac and 213Bi (and thus 221Fr), the calibration factors for EW 213Bi ($CF_{\text{213Bi}}$) and EW 221Fr ($CF_{\text{221Fr}}$) were determined from GC measurements as:

$$CF_{\text{213Bi}} = \frac{CPM_{\text{EW 213Bi}}}{A_{\text{225Ac}}}$$ (2)

$$CF_{\text{221Fr}} = \frac{CPM_{\text{EW 221Fr}}}{A_{\text{225Ac}}}$$ (3)

If there is SEq between 225Ac and 221Fr but not between 225Ac and 213Bi, we want to have the CPM measured with EW 221Fr to be independent of the 213Bi activity. Therefore, we needed to correct for the down scatter of the higher high-energy gamma rays of 213Bi into the EW 221Fr (Fig. 1). Hence, the scatter contribution of 213Bi to EW 221Fr ($CPM_{\text{213Bi\rightarrow EW 221Fr}}$) was determined as function of $CPM_{\text{EW 213Bi}}$ by performing GC measurements using both EW 221Fr and EW 213Bi for a pure 213Bi sample which was measured for more than 5 h to cover different $CPM_{\text{EW 213Bi}}$ values. As such GC measurements using the EW 221Fr can be corrected for the 213Bi down scatter by subtracting the activity-dependent scatter contribution of 213Bi to the EW 221Fr using the following expression:

$$CPM_{\text{SC,EW 221Fr}} = CPM_{\text{EW 221Fr}} - CPM_{\text{213Bi\rightarrow EW 221Fr}}$$ (4)

![Fig. 1 GC photon energy spectrum measured for 225Ac, in SEq with both 221Fr and 213Bi, and for pure 213Bi](image-url)
This resulted in a calibration factor for the scatter-corrected EW\textsubscript{221Fr} to accurately estimate 225\textsuperscript{Ac} activities independent of 213\textsuperscript{Bi} activities:

\[
CF_{SC,221\text{Fr}} = \frac{CPM_{SC,EW\text{221Fr}}}{A_{225\text{Ac}}}
\]  

(5)

**Multiple time-point GC measurements to quantify 225\textsuperscript{Ac} doped with 213\textsuperscript{Bi}**

Immediately after preparation of the two samples with an additional amount of 213\textsuperscript{Bi} activity (compared to 213\textsuperscript{Bi} activity in SEq with 225\textsuperscript{Ac}), GC measurements were performed sequentially, at intervals of 5 min, for a total duration of 5–6 h after preparation, using the EW\textsubscript{213Bi} and corresponding CF\textsubscript{213Bi}.

Given \(A_{0225\text{Ac}}\), the initial activity of 213\textsuperscript{Bi} in SEq with 225\textsuperscript{Ac}, and \(A_{0213\text{Bi}}\) the additional amount of 213\textsuperscript{Bi} activity at the start of the measurement (\(t=0\)), the total activity of 213\textsuperscript{Bi} at time \(t\) is given by (see Eqs. 1, 2):

\[
A_{total,213\text{Bi}}(t) = A_{0225\text{Ac}} \times e^{-\lambda_{225\text{Ac}} t} + A_{0213\text{Bi}} \times e^{-\lambda_{213\text{Bi}} t}
\]

(6)

with \(CPM_{EW\text{213Bi}}(t)\) the GC measurement at time \(t\) using EW\textsubscript{213Bi} and with \(\lambda_{225\text{Ac}}\) and \(\lambda_{213\text{Bi}}\) the physical decay constants for 225\textsuperscript{Ac} and 213\textsuperscript{Bi} respectively. Therefore, GC measurements using EW\textsubscript{213Bi} were analyzed as a function of time \(t\) after start of the measurement and used to determine the initial 213\textsuperscript{Bi} activity in SEq with 225\textsuperscript{Ac} and the additional amount of 213\textsuperscript{Bi} at the start of the GC measurement. This was done by non-linear least squares fitting (GraphPad Prism version 9.1.0) of a double exponential function to the GC measurements at different time-points with the physical decay constants fixed.

**Single time-point GC measurements to quantify 225\textsuperscript{Ac} doped with 213\textsuperscript{Bi}**

In the second approach, a single time-point GC measurement using both EW\textsubscript{221Fr} and EW\textsubscript{213Bi} was considered, which theoretically should allow an estimation of both 225\textsuperscript{Ac} activity in SEq with 213\textsuperscript{Bi} and an additional amount of 213\textsuperscript{Bi} activity. This approach assumes one single GC measurement after SEq is reached between 225\textsuperscript{Ac} and 221\textsuperscript{Fr} (after ~30 min), but as soon as possible thereafter, to ensure that any 213\textsuperscript{Bi} present in the sample has not yet reached SEq with 225\textsuperscript{Ac}. This way, one can still differentiate between the amount of 213\textsuperscript{Bi} activity in SEq with 225\textsuperscript{Ac} and the additional amount of 213\textsuperscript{Bi} activity. If we assume the single time-point GC measurement at time \(t\) after sample preparation, the additional amount of 213\textsuperscript{Bi} activity at the start of the measurement (\(A_{0213\text{Bi}}\)) can be estimated using the EW\textsubscript{213Bi} once the initial activity of 225\textsuperscript{Ac} (\(A_{0225\text{Ac}}\)) at the start of the measurement is known:

\[
A_{0213\text{Bi}} = \left(\frac{CPM_{EW\text{213Bi}}(t)}{CF_{213\text{Bi}}} - A_{0225\text{Ac}} \times e^{-\lambda_{225\text{Ac}} t}\right) \times e^{\lambda_{213\text{Bi}} t}
\]

(7)

with \(CPM_{EW\text{213Bi}}(t)\) the GC measurement at time \(t\) using EW\textsubscript{213Bi} and with \(\lambda_{225\text{Ac}}\) and \(\lambda_{213\text{Bi}}\) the physical decay constant for 225\textsuperscript{Ac} and 213\textsuperscript{Bi} respectively. In turn, the initial activity of 225\textsuperscript{Ac} (\(A_{0225\text{Ac}}\)) can be estimated using the EW\textsubscript{221Fr} either from:

\[
A_{0225\text{Ac}} = \frac{CPM_{EW\text{221Fr}}(t)}{CF_{221\text{Fr}}} \times e^{\lambda_{225\text{Ac}} t}
\]

(8)
with $CPM_{\text{EW}221\text{Fr}}(t)$ the GC measurement at time $t$ using EW$_{221\text{Fr}}$ without scatter correction (see Eq. 3), or from:

$$A^0_{225\text{Ac}} = \frac{CPM_{\text{SC,EW}221\text{Fr}}(t)}{CF_{\text{SC,221Fr}}} \times e^{\frac{t}{\lambda_{225\text{Ac}}}}$$  \hspace{1cm} (9)$$

with $CPM_{\text{SC,EW}221\text{Fr}}(t)$ the GC measurement at time $t$ using EW$_{221\text{Fr}}$ with scatter correction (see Eq. 5). In both Eq. 8 and Eq. 9, $\lambda_{225\text{Ac}}$ represents the physical decay constant for $^{225}\text{Ac}$.

Both Eqs. 8 and 9 were considered to estimate the initial activity of $^{225}\text{Ac}$ using EW$_{221\text{Fr}}$.

Quantification of the bound fraction of $^{225}\text{Ac}$ and $^{213}\text{Bi}$ during radiopharmaceutical QC of $[^{225}\text{Ac}]\text{Ac-DEPA}$ and $[^{225}\text{Ac}]\text{Ac-DOTA}$ complexes

As a direct application, we performed GC measurements at multiple time-points during the stability test of two constructs, $[^{225}\text{Ac}]\text{Ac-DEPA}$ and $[^{225}\text{Ac}]\text{Ac-DOTA}$, as part of radiopharmaceutical QC. For this stability test, two ethanolic solutions of 50 μL, each containing one of the constructs, were added immediately after purification to 450 μL of human serum and incubated at 37 °C. Samples were collected at 15 min and 24 h post reaction. The RCY of each reaction mixture was determined by instant thin-layer liquid chromatography (iTLC-SG, Varian, Diegem, Belgium) with an elution chamber using acetonitrile/water (75%/25% v/v) such that bound $^{225}\text{Ac}$ and bound daughter radionuclides will migrate with the solvent front to the upper part of the iTLC strip, while unbound radionuclides will remain at the lower part where the mixture was originally spotted (Fig. 2) (Cassells et al. 2021). Once the solvent front reached the 1-cm mark of the iTLC strip at time $t_i$ (cfr solvent front Fig. 2), the iTLC strip is removed from the mobile phase and cut in half. Immediately after, the activity of the upper and lower parts of the iTLC strip were measured with GC using both EW$_{221\text{Fr}}$ and EW$_{213\text{Bi}}$ with the previously described energy window settings.

**Fig. 2** Schematic representation of the migration of radiolabeled compounds in the iTLC strip. Upon exposure of the strip to the mobile phase, unbound radionuclides will remain in the spotting site, whereas bound radionuclides will move with the solvent front to the upper part of the iTLC strip.
The $^{225}$Ac activity was estimated for each part of the iTLC strip using a single time-point GC measurement after more than 5 h to ensure SEq between $^{225}$Ac and $^{213}$Bi such that the $^{225}$Ac activity could be estimated from the CPM data acquired with $\text{EW}_{213\text{Bi}}$ and extrapolated to the start of the iTLC elution at $t_0$.

In addition, a single time-point measurement was performed at 30 min after starting the iTLC elution to ensure SEq between $^{225}$Ac and $^{221}$Fr such that the $^{225}$Ac activity could be estimated from the CPM acquired with $\text{EW}_{221\text{Fr}}$ with (Eq. 9) and without scatter correction (Eq. 8). Next, the increase (or decrease) in $^{213}$Bi activities compared to SEq (dependent on the part of the strip) was estimated from the CPM acquired with $\text{EW}_{213\text{Bi}}$. In case of an increase of $^{213}$Bi, the $^{213}$Bi activity at the start of the iTLC elution ($t_0$) was estimated using Eq. 7.

For the upper part of the iTLC strips obtained after 24 h of incubation in human serum, multiple time-point measurements were performed before SEq between $^{225}$Ac and $^{213}$Bi (> 5 h) while only the CPM data acquired with the $\text{EW}_{213\text{Bi}}$ were used for the analysis. In case of increased or reduced $^{213}$Bi activity compared to SEq with $^{225}$Ac, fitting of a double exponential function (i.e. Eq. 6) was performed by non-linear least squares fitting (GraphPad Prism version 9.1.0) to the multiple GC measurements at different time-points. For both $^{225}$Ac and $^{213}$Bi, the bound fraction was determined as the ratio of the activity of either radionuclide measured for the upper part of the iTLC over the sum of activities measured for both the upper and the lower part of the iTLC.

**Results**

$^{225}\text{Ac}/^{213}\text{Bi}$ samples and $[^{225}\text{Ac}]$-labeled constructs

Table 1 gives an overview of the different samples for GC measurements and the activity at the start of the measurements. To evaluate the GC linearity a total of 19 test samples were prepared from sample 1. The samples were prepared with equal volume (0.5 mL), to avoid a volume effect on sensitivity, and with varying activities ranging from 1 Bq up to 500 kBq of $^{225}$Ac in SEq with $^{221}$Fr and $^{213}$Bi.

**Gamma counter measurements**

For both EW setting for $^{221}$Fr and $^{213}$Bi, the GC response expressed as count rate (CPM) was measured as a function of the different activities obtained from sample 1 which was

| Sample | $^{225}\text{Ac}$ (in SEq with $^{213}\text{Bi}$) | Added $^{213}\text{Bi}$ | Experiment |
|--------|---------------------------------|-------------------|------------|
| 1      | 1.5 MBq (total)                 | 0 kBq             | GC calibration |
| 2      | 0 kBq                          | 117 kBq           | Quantifying down scatter of higher-energy gamma emissions by $^{211}\text{Bi}$ in $\text{EW}_{221\text{Fr}}$ |
| 3      | 94 kBq                         | 55 kBq            | Simulating non-SEq conditions between $^{225}\text{Ac}$ and $^{213}\text{Bi}$ |
| 4      | 116 kBq                        | 32 kBq            | Radiolabeling of $[^{225}\text{Ac}]{\text{Ac-DOTA}}$ and incubation in human serum for 15 min and 24 h |
| 5      | 1–2 MBq                        | 0 kBq             | Radiolabeling of $[^{225}\text{Ac}]{\text{Ac-DEPA}}$ and incubation in human serum for 15 min and 24 h |

Specifications of the samples used for determining the linear range of GC measurements and evaluating the impact of different sample volumes on GC measurements is given in the Additional file 1.
cross-calibrated with a standard HPGe detector (see Fig. 3). A non-linearity of more than 3% in the GC response was observed for activities above 150 kBq, resulting in a CPM underestimation of up to 17% and 25% for activities around 0.5 MBq when using the EW 221Fr and the EW 213Bi respectively. Therefore, GC response was considered linear up to 150 kBq 221Fr and 213Bi, in SEq with 225Ac. For this linear range, CFs were determined by linear regression, resulting in GC CFs for the EWs of 213Bi (CF213Bi) and 221Fr (CF221Fr) of 6.1E+06 CPM/MBq and 7.4E+06 CPM/MBq, respectively. The CPMs obtained with GC using the EW 221Fr (CPM213Bi→EW221Fr) are shown as a function of different CPM measured with the EW 213Bi (CPM213Bi) for different 213Bi activities obtained from a cross-calibration with the HPGe detector (see Fig. 4). Results indicated a clear, linear relationship between CPM213Bi→EW221Fr and CPM213Bi (linear regression, slope = 0.205 ± 0.001, R² > 0.99) which can be used to estimate the scatter contribution of 213Bi to GC measurements in the EW 221Fr. This scatter fraction can be subtracted from EW 221Fr, and 225Ac activities can be accurately estimated even when there is no SEq between 225Ac and 213Bi.

Fig. 3  GC response for 225Ac in SEq with 221Fr and 213Bi, measured with both EWs of 221Fr and 213Bi. Error bars represent the standard deviation provided by the GC software.

Fig. 4  Count rate of the down scatter of gamma emissions by 213Bi in the EW 221Fr (CPM213Bi→EW221Fr) for different count rates of 213Bi measured with the EW 213Bi (CPM213Bi).
(Eq. 9). The corresponding GC calibration factor for the EW\textsubscript{221Fr}, when a correction for \textsuperscript{213}Bi photon down scatter is applied, was determined as 6.1E+06 CPM/MBq.

**Multiple time-point GC measurements to quantify \textsuperscript{225}Ac doped with \textsuperscript{213}Bi**

For the multiple time-point approach, activities measured by the gamma counter using EW\textsubscript{213Bi} are plotted as a function of the measurement time for the sample 3 (see Table 1) containing \textsuperscript{213}Bi activity in SEq with \textsuperscript{225}Ac and an additional amount of \textsuperscript{213}Bi activity (see Fig. 5). Based on a bi-exponential fit with fixed physical decay constants for \textsuperscript{225}Ac and \textsuperscript{213}Bi (cfr Eq. 6), \textsuperscript{225}Ac and \textsuperscript{213}Bi activities were estimated (see Table 2), both with a relative percentage difference lower than 3% compared to the reference activities determined with the HPGe detector.

---

**Table 2** Multiple and single time-point (at 30 min) estimation of the \textsuperscript{225}Ac and \textsuperscript{213}Bi activity for sample 3 and 4 containing \textsuperscript{213}Bi in SEq with \textsuperscript{225}Ac and an additional amount of \textsuperscript{213}Bi

| Sample 3                  | \textsuperscript{213}Bi (SEq with \textsuperscript{225}Ac) | Added \textsuperscript{213}Bi |
|---------------------------|---------------------------------------------------------|-----------------------------|
|                           | CPM\textsubscript{EW\textsubscript{213Bi}} | kBq | %diff | kBq | %diff |
| Multiple time-points      | 93.7                                                    | < 3 |      | 54.9 | < 3   |
| Single time-point at 30 min | 101.8                                                  | 9   | 47.0  | < 15 |
| Single time-point at 30 min (scatter corrected) | 93.4                                                   | < 3 |      | 55.3 | < 3   |

| Sample 4                  | \textsuperscript{213}Bi (SEq with \textsuperscript{225}Ac) | Added \textsuperscript{213}Bi |
|---------------------------|---------------------------------------------------------|-----------------------------|
|                           | CPM\textsubscript{EW\textsubscript{213Bi}} | kBq | %diff | kBq | %diff |
| Multiple time-points      | 116.2                                                   | < 3 |      | 32.9 | < 3   |
| Single time-point at 30 min | 122.9                                                  | 6   | 28.4  | < 11 |
| Single time-point at 30 min (scatter corrected) | 116.7                                                   | < 3 |      | 32.8 | < 3   |

Corresponding CPM approaches are indicated and the relative difference (%diff) compared to the reference activities in both samples.
Single time-point GC measurements to quantify $^{225}\text{Ac}$ doped with $^{213}\text{Bi}$

For the single time-point approach, $^{225}\text{Ac}$ activities measured with $^{221}\text{Fr}$ with and without scatter correction are plotted as function of time for the sample 3 containing $^{225}\text{Ac}$ in SEq with $^{213}\text{Bi}$ and additional $^{213}\text{Bi}$ activity (Fig. 6A). This measurement was started after SEq was reached between $^{221}\text{Fr}$ and $^{225}\text{Ac}$ (~30 min) such that $^{225}\text{Ac}$ activity could be estimated from the CPMs measured within $^{221}\text{Fr}$. When no scatter correction was applied, $^{225}\text{Ac}$ activities showed an overestimation due to the additional down scatter of gamma-emissions by the added $^{213}\text{Bi}$ activity. The overestimation gradually decreased because of the decay of this additional $^{213}\text{Bi}$ till SEq was again reached between $^{225}\text{Ac}$ and $^{213}\text{Bi}$ (Fig. 6B). Applying a correction for down scatter of $^{213}\text{Bi}$ gamma emissions in the $^{221}\text{Fr}$ reduces this overestimation of $^{225}\text{Ac}$ activities. For a single time-point GC measurement at 30 min, omission of the scatter correction resulted in an overestimation of 6 to 9% of the $^{225}\text{Ac}$ activity while the estimated activity was within 3% of the reference value when scatter correction was applied. When using the estimated $^{225}\text{Ac}$ activity to determine the additional $^{213}\text{Bi}$ activity, this resulted in an underestimation of 11 to 15% when no scatter correction was applied and while it was within 3% of the reference activity after applying a correction for down scatter (Table 2).

Quantification of $^{225}\text{Ac}$ and $^{213}\text{Bi}$ during radiopharmaceutical QC of $^{225}\text{Ac}$-DEPA and $^{225}\text{Ac}$-DOTA complexes

An overview of the bound fraction of $[^{225}\text{Ac}]$Ac-DEPA/DOTA after a 15 min and 24 h incubation in human serum is given in Table 3. These estimates are based on single time-point GC measurement protocols.

Multiple time-point GC measurements, performed of the upper part of iTLC strip for the 24 h incubation time in human serum using $^{213}\text{Bi}$ (see Fig. 7), showed an ingrowth of $^{213}\text{Bi}$ for both $[^{225}\text{Ac}]$Ac-DOTA and $[^{225}\text{Ac}]$Ac-DEPA until SEq was again restored between $^{225}\text{Ac}$ and $^{213}\text{Bi}$ after 5 h (i.e. $^{213}\text{Bi}$ reached ~99% of $^{225}\text{Ac}$ activity). These findings correspond to a lower fraction of bound $^{213}\text{Bi}$ compared to the fraction of bound $^{225}\text{Ac}$.

Fig. 6 A $^{225}\text{Ac}$ activities measured with $^{221}\text{Fr}$, with and without scatter correction are plotted as function of measurement time for the sample 3 (see Table 1) containing $^{225}\text{Ac}$ and additional $^{213}\text{Bi}$ activity. Error bars represent the standard deviation provided by the GC software. B Relative bias (percentage relative difference) of $^{225}\text{Ac}$ activity estimated using $^{221}\text{Fr}$ as function of the added $^{213}\text{Bi}$ activity (compared to SEq between $^{225}\text{Ac}$ and $^{213}\text{Bi}$) when no correction for the additional down scatter of $^{213}\text{Bi}$ gamma-emissions in the $^{221}\text{Fr}$ is applied.
For $^{225}\text{Ac}$ activities were determined with a single time-point GC measurement using $^{213}\text{Bi}$ at 5 h, to ensure SEq between $^{213}\text{Bi}$ and $^{225}\text{Ac}$, and using $^{221}\text{Fr}$ with and without scatter correction at 30 min, to ensure SEq between $^{221}\text{Fr}$ and $^{225}\text{Ac}$.
long waiting time can prove to be challenging from a practical point of view, it also prevents the quantification of $^{213}$Bi activities before SEq with $^{225}$Ac. This information is however needed to monitor the relocation of free $^{213}$Bi, released from the molecular vector, from the tumor site or tissues showing target expression to organs involved in excretory pathway of $^{213}$Bi. A straightforward approach to avoid the need for SEq between $^{225}$Ac and $^{213}$Bi when using the EW of $^{213}$Bi for $^{225}$Ac quantification, is a multiple GC measurement protocol where activities are measured at different time points before and/or during SEq between $^{225}$Ac and $^{213}$Bi. As the approach does not require SEq, neither between $^{225}$Ac and $^{213}$Bi nor between $^{225}$Ac and $^{221}$Fr, GC measurements can be initiated as soon as samples are available to ensure that the highest activity of $^{213}$Bi can be measured. This can be very useful for biodistribution studies where the $^{213}$Bi activity in the different organs is not known in advance and sensitivity to pick up even low levels of $^{213}$Bi activities should be maximized. For our experiments, we performed measurements every 5 min to demonstrate feasibility but in practice, the optimal timing for the measurements will depend on the number of samples which need to be counted and the availability of the GC system. However, we would advise to maximize the number of measurements to reduce the impact of noise, since $^{213}$Bi activities are expected to be rather low in preclinical biodistribution and radiotoxicity studies on rodents (Kruijff et al. 2019; Miederer et al. 2004a, 2008; Poty et al. 2019; Nedrow et al. 2017; Schwartz et al. 2011). In addition, this approach using multiple GC measurements could also be considered for monitoring whether $^{221}$Fr activities are different from the activities expected for SEq with $^{225}$Ac. However, non-SEq between $^{221}$Fr and $^{225}$Ac is generally considered irrelevant and challenging to assess, due to its relatively short physical half-life of only a few minutes. Moreover, because $^{221}$Fr is the first gamma-emitting daughter in the decay chain of $^{225}$Ac, with this short half-life, it is generally considered as the closest proxy daughter to determine the presence/location and activity of $^{225}$Ac.

Therefore, we suggested a single GC measurement to determine the $^{225}$Ac activity using the EW of $^{221}$Fr. This can be done once SEq is established between $^{225}$Ac and $^{221}$Fr around 30 min after mixed $^{225}$Ac/$^{213}$Bi samples have been synthetized as was previously reported (Hooijman et al. 2021; Pretze et al. 2021). However, we noticed that $^{225}$Ac activity estimated with the EW of $^{221}$Fr is biased when the activity of $^{213}$Bi does not correspond with the expected activity in case of SEq with $^{225}$Ac. This problem can be addressed by using a HPGe detector due to its superior energy resolution which provides a more definite isotopic identification for low-energy emitters than NaI(Tl) detectors (Perez-Andujar and Pibida 2004). However, the purpose of this study was to optimize the GC protocols because these detectors are much more accessible than HPGe detectors. Moreover, commercial GC systems allow automatic measurements of many samples, making it a very suitable technique for the multiple time point protocols that were used for this study. Therefore, we advise to estimate the down scatter of the higher-energy gamma rays by $^{213}$Bi into the EW of $^{221}$Fr when using GC protocols. This way, the count rate in the EW of $^{221}$Fr can be corrected, such that $^{225}$Ac-estimates using the EW of $^{221}$Fr are unbiased and independent of the $^{213}$Bi activity present in the sample or mixture. Once $^{225}$Ac activity has been determined, the remaining $^{213}$Bi activity can be estimated using the EW of $^{213}$Bi. However, this single GC measurement approach requires a waiting time of around 30 min which reduces the sensitivity for measuring low amounts of $^{213}$Bi compared to a GC
measurement protocol using multiple time points. On the other hand, a single GC measurement protocol can be considered when higher levels of $^{213}$Bi activities are anticipated, like for example during the synthesis of $^{225}$Ac-labeled radiopharmaceuticals, or when standardized QC procedures need to be balanced between unbiased activity estimates and short measurement times. A single GC measurement at 2 h after radiolabeling was already suggested as ideal time point for GC measurements to balance the need for a fast release and accurate assessment of the radiochemical yield (Kelly et al. 2021; Eryilmaz and Kilbas 2021). However, one could argue that 2 h waiting time will delay administration to patients, while the bound fraction of both $^{213}$Bi and $^{225}$Ac will be reduced to the RDE. Therefore, a GC measurement protocol at 30 min to indirectly quantify $^{225}$Ac activity by measuring $^{221}$Fr once SEq is reached between $^{225}$Ac and $^{221}$Fr, can be a valid alternative, provided that a correction is applied for the down scatter of the higher-energy gamma emissions by $^{213}$Bi.

For our study, we used both single and multiple time-point GC measurements to evaluate the stability of $[^{225}\text{Ac}]$Ac-DEPA and $[^{225}\text{Ac}]$Ac-DOTA constructs in human serum to simulate an in vivo situation and challenge the radiocomplexes to test their stability (e.g. transeptation by metalloproteins). After 24 h of incubation in human serum, negligible amount of bound $^{213}$Bi were observed for both constructs based on the GC measurements of the upper part of the iTLC strips just after elution (see Fig. 7). Following the GC measurements, $^{213}$Bi activity gradually recovered till SEq was reached with $^{225}$Ac, and $^{213}$Bi activity was again representative for the fraction of bound $^{225}$Ac. These findings showed that, after 24 h incubation in human serum, $^{213}$Bi was not bound to the chelator anymore and was most likely released due to the RDE, while the fraction of bound $^{225}$Ac remained very high (Kratochwil et al. 2016) and very stable for both constructs (see Table 3). To reduce potential radiotoxicity caused by the RDE, diethylenetriamine pentaacetic acid (DTPA, hydrophilic chelate) can be added to the final formulation buffer for complexation of free $^{225}$Ac and recoiled daughters before administration and combined with diuretic drugs to increase renal excretion (Kratochwil et al. 2016). However, once administered, the $^{225}$Ac-labeled compound is being added to a diluted medium, such as blood pool, and $^{213}$Bi will still be released and cause additional radiotoxicity because of RDE. This can justify, to some extent, the high uptake of free $^{213}$Bi in healthy (i.e. non-targeted) organs (e.g. kidneys Kruijff et al. 2019; Song et al. 2009; Drecoll et al. 2009) early after injection. Ideally, this risk of potential redistribution and additional radiotoxicity should be minimized by using more stable targeting systems with high radiolabeling yields capable of retaining part of the daughter nuclides or strategies to retain radionuclides in the tumor cells/tissues (Kruijff et al. 2019; Robertson et al. 2018).

In terms of clinical translation, one could consider using the proposed GC protocols to quantify activity levels of $^{225}$Ac and $^{213}$Bi in blood and urine samples of patients undergoing $^{225}$Ac -TAT. This way, renal, bone marrow, urinary bladder wall, or gastrointestinal toxicity can be estimated and whole-body clearance can be monitored in a more patient-specific manner, contrary to the more empirically dose estimates to OARs based on the retrospective evaluation of radiotoxicity and treatment response in groups of patients (Siegel et al. 1999). Moreover, accurate GC measurements of the $^{225}$Ac and $^{213}$Bi activity levels in patient samples could be combined with compartmental models to unravel the biokinetics of $^{225}$Ac-pharmaceuticals and recoiling
daughters for a better dosimetry (Hooijman et al. 2021), such to allow better prediction of radiotoxicity and treatment efficacy in patients.

The main limitation of this study is the limited number of experiments because of the limited availability of $^{225}$Ac. Therefore, the proposed GC protocols should be further validated and especially the time schedule of the multiple GC measurements for each specific application.

Conclusions
For this study, we evaluated two GC measurement protocols for quantifying $^{225}$Ac-activity when no SEq is guaranteed between $^{225}$Ac and its daughter radionuclide $^{213}$Bi. A first protocol performed multiple measurements using only the $^{213}$Bi energy window and requires no secular equilibrium between $^{225}$Ac and its gamma emitting daughter radionuclides. For the second protocol, SEq was required between $^{225}$Ac and $^{221}$Fr corresponding to a waiting time of around 30 min but only one measurement was needed using both the $^{213}$Bi and $^{221}$Fr energy window. Both protocols were able to accurately estimate $^{225}$Ac-activities provided the $^{221}$Fr energy window was corrected for the down scatter of the higher-energy gamma-emissions by $^{213}$Bi. In addition, these two protocols were able to quantify $^{213}$Bi-activities which cannot be attributed to the parent-daughter decay of $^{225}$Ac. From this perspective, a multiple GC measurement protocol could prove more sensitive to pick up low levels of $^{213}$Bi since it doesn’t require SEq and allows measurements as soon as samples are available. This could prove beneficial to study the recoil daughter effect and redistribution of free $^{213}$Bi by monitoring the accumulation or clearance of $^{213}$Bi in different tissues during biodistribution studies or in patient samples during clinical studies. On the other hand, the single GC measurement protocol, although required a 30 min waiting time, is more time and cost efficient and therefore more appropriate for standardized QC procedures of $^{225}$Ac-labeled radiopharmaceuticals.

Abbreviations

- CF: Calibration factor
- CPM: Counts per minute
- DOTA: 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetracetic acid
- DEPA: 7-[2-(Bis-carboxymethyl-amino)-ethyl]-4,10-bis-carboxymethyl-1,4,7,10-tetraazacyclododec-1-yl-acetic acid
- DTPA: Diethylenetriamine pentaacetic acid
- EW: Energy window
- GC: Gamma counter
- iTLC: Instant thin-layer liquid chromatography
- LET: Linear energy transfer
- QC: Quality control
- RDE: Recoil daughter effect
- SEq: Secular equilibrium
- SPECT: Single photon emission computed tomography
- TAC: Time–activity curves
- TAT: Targeted alpha-particle therapy

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s41181-022-00174-z.

Additional file 1: Fig. S1. Relative counting efficiency of the GC as function of sample volume for the quantification of $^{225}$Ac using the $^{213}$Bi and $^{221}$Fr EW. Design and results of an additional experiment to study the effect of sample volume on the relative GC detector efficiency.
Acknowledgements
We thank Stephan Heinitz and Hongshan Zhu for their technical assistance during the preparation of the $^{225}$Ac/$^{213}$Bi generator.

Author contributions
DCS: experimental design, experimental setup, data analysis, discuss data analytics, draft manuscript. MDSH: methodology, discuss data analytics, draft manuscript. SA: experimental design, experimental setup, radiopharmaceutical radiolabeling, discuss data analytics, writing-review. CSV: experimental design, discuss data analytics, methodology, writing-review. MO: radiopharmaceutical radiolabeling, discuss data analytics, review. LS: methodology, discuss data analytics, writing-review. All authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
All data generated or analysed during this study are included in this published article and its supplementary information files.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.

Received: 8 June 2022   Accepted: 22 August 2022

Published online: 23 October 2022

References
Ahenkorah S, Cassells I, Deroose CM, Cardinaels T, Burgoyne AR, Bormans G et al. Bismuth-213 for targeted radionuclide therapy: from atom to bedside. Pharmaceutics. 2021;13:1–25. https://doi.org/10.3390/pharmaceutics13050599.

Allen B, Huang C-Y, Clarke R. Targeted alpha anticancer therapies: update and future prospects. Biol Targets Ther. 2014;8:25S. https://doi.org/10.2147/BTT.S29947.

Ballal S, Yadav MP, Bal C, Sahoo RK, Tripathi M. Broadening horizons with $^{225}$Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to $^{177}$Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety. Eur J Nucl Med Mol Imaging. 2020;47:934–46. https://doi.org/10.1007/s00259-019-04567-2.

Beyer GJ, Bergmann R, Schomäcker K, Rösch F, Schäfer G, Kulikov EV et al. Comparison of the biodistribution of $^{225}$ Ac and radio-lanthanides as citrate complexes. Isot Isot Environ Heal Stud. 1990;26:111–4. https://doi.org/10.1080/10256019008624245.

Boden S, Vints K, Cagno S, Maertens D, Van Hecke K, Cardinaels T. Thorium-229 quantified in historical Thorium-228 capsules. Appl Radiat Isot. 2017;120:40–4. https://doi.org/10.1016/J.APRADISO.2016.11.012.

Borchardt PE, Yuan RR, Miederer M, McDevitt MR, Scheinberg DA. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res. 2003;63:5084–90.

Cassells I, Ahenkorah S, Burgoyne AR, Van de Voorde M, Deroose CM, Cardinaels T et al. Radiolabeling of human serum albumin with terbium-161 using mild conditions and evaluation of in vivo stability. Front Med. 2021;8:1–12. https://doi.org/10.3389/fmed.2021.675122.

Castillo Seoane D, de Saint-Hubert M, Grabbe M, Stuevelens L, Koole M. Targeted alpha therapy: a critical review of translational dosimetry research with emphasis on actinium-225. Q J Nucl Med Mol Imaging 2020;64:265–77. https://doi.org/10.23736/S1824-4785.20.03266-5.

Cordier D, Forrer F, Bruchertseifer F, Morgenstern A, Apostolidis C, Good S et al. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8, Met(O2)11]- substance P. A pilot trial. Eur J Nucl Med Mol Imaging. 2010;37:1335–44. https://doi.org/10.1007/s00259-010-1385-5.

de Kruijf RM, Wolterbeek HT, Denkova AG. A critical review of alpha radionuclide therapy-how to deal with recoiling daughters? Pharmaceuticals. 2015;8:321–36. https://doi.org/10.3390/ph8020321.

Drecoll E, Gaertner FC, Miederer M, Blechert B, Vallon M, Müller JM et al. Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide 213Bi-DTPA-[F3]2 into the nucleus of tumor cells. PLoS ONE. 2009;4:e5715. https://doi.org/10.1371/journal.pone.0005715.

Eryilmaz K, Kilbas B. Detailed chemistry studies of 225Actinium labeled radiopharmaceuticals. Curr Radiopharm. 2021. https://doi.org/10.2174/187447101466610528123936.

Hooijman EL, Chalashkan Y, Ling SW, Kahyargil FF, Segbers M, Bruchertseifer F et al. Development of (225Ac)Ac-PSMA-I&T for targeted alpha therapy according to GMP guidelines for treatment of mCRPC. Pharmaceuticals. 2021. https://doi.org/10.3390/pharmaceutics13050715.
Kelly JM, Amor-Coarasa A, Sweeney E, Wilson JJ, Causey PW, Babich JW. A suitable time point for quantifying the radiochemical purity of 225Ac-labeled radiopharmaceuticals. EJNMMI Radiopharm Chem. 2021. https://doi.org/10.1186/s41181-021-00151-y.

Khreish F, Ebert N, Ries M, Maus S, Rosar F, Boehnenger H et al. 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging. 2020;47:721–8. https://doi.org/10.1007/s00259-019-04612-0.

Kozempel J, Molkhotdeva O, Vlk M. Progress in targeted alpha-particle therapy. What we learned about recoils release from in vivo generators. Mol A J Synth Chem Nat Prod Chem. 2018. https://doi.org/10.3390/MOLECULES23030581.

Kratochwil C, Giesel FL, Bruchtseifer F, Mier W, Apostolidis C, Boll R et al. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014;41:2106–19. https://doi.org/10.1007/s00259-014-2857-9.

Kratochwil C, Bruchterseifer F, Giesel F, Apostolidis C, Haberkorn U, Morgenstern A. Ac-225-DOTATOC—dose finding for alpha particle emitter based radionuclide therapy of neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2015;42:1–924. https://doi.org/10.1007/s00259-015-3198-z.

Kratochwil C, Bruchterseifer F, Giesel FL, Weiss M, Verburg FA, Mottaghy F et al. 225Ac-PSMA-617 for PSMA targeting alpha-radiation therapy of patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941–4. https://doi.org/10.2967/jnumed.116.178673.

Kratochwil C, Bruchterseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W et al. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med. 2017;58:1624–31. https://doi.org/10.2967/jnumed.117.191395.

Kruijff RMD, Raavé R, Kip A, Molkenboer-Kuenen J, Morgenstern A, Bruchterseifer F et al. The in vivo fate of 225Ac daughter nuclides using polymersomes as a model carrier. Sci Rep. 2019;9:1–13. https://doi.org/10.1038/s41598-019-48298-8.

Miederer M, McDevitt MR, Sgouros G, Kramer K, Cheung NK, Scheinberg DA. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. J Nucl Med. 2004;45:129–37.

Miederer M, McDevitt MR, Borchardt P, Bergman I, Kramer K, Cheung NK et al. Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of α-emitting atomic nanogenerators targeting disialo-ganglioside GD2. Clin Cancer Res. 2004;10:6985–92. https://doi.org/10.1158/1078-0432.CCR-04-0859.

Miederer M, Henriksen G, Alke A, Mossbrugger I, Quintanilla-Martinez L, Senekowitsch-Schmidtke R et al. Preclinical evaluation of the α-particle generator nuclide 225Ac for somatostatin receptor radiotargeting of neuroendocrine tumors. Clin Cancer Res. 2008;14:3555–61. https://doi.org/10.1158/1078-0432.CCR-07-4647.

Nedrow JR, Josefsson A, Park S, Back T, Hobbs RF, Brayton C et al. Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model. EJNMMI Res. 2017;7:57. https://doi.org/10.1186/s13550-017-0303-2.

Perez-Andujar A, Pibida L. Performance of CdTe, HPGe and NaI(Tl) detectors for radioactivity measurements. Appl Radiat Isot. 2004;60:41–7. https://doi.org/10.1016/J.APRADISO.2003.10.006.

Pretze M, Kunkel F, Runge R, Freudenberg R, Braune A, Hartmann H et al. Ac-EAZY! towards GMP-compliant module syntheses of 225 Ac-labeled peptides for clinical application. Pharmaceuticals (basel). 2021;14:652. https://doi.org/10.3390/PH14070652.

Poty S, Carter LM, Mandlewala K, Membreno R, Abdel-Atti D, Ragupathi A et al. Leveraging bioorthogonal click chemistry to improve 225 AC-radioimmunoconjugates of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2019;25:868–80. https://doi.org/10.1158/1078-0432.CCR-18-1650.

Robertson AKH, Ramogida CF, Schaffer P, Radchenko V. Development of 225Ac radiopharmaceuticals: TRIUMF perspectives and experiences. Curr Radiopharm. 2018;11:156–72. https://doi.org/10.2174/1874471011666180416161908.

Schwartz J, Jaggi JS, O'Donoghue JA, Ruan S, McDevitt M, Larson SM et al. Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody. Phys Med Biol. 2011;56:721–33. https://doi.org/10.1088/0031-9155/56/3/012.

Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40:57–61.

Song H, Hobbs RF, Vajravelu R, Huso DL, Esaias C, Apostolidis C et al. Radioimmunotherapy of breast cancer metastases with alpha-particle-emitter 225Ac: comparing efficacy with 213Bi, 90Y. Cancer Res. 2009;69:8941. https://doi.org/10.1158/0008-5472.CAN-09-1828.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.